Shilpa Medicare receives USFDA approval for Varenicline tablets

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

02 May 2025 00:00:00

Adani Ports

1267.05

(4.11%)

Asian Paints

2409.45

(-0.57%)

Axis Bank

1182.15

(-0.15%)

Bajaj Finance

8862.25

(2.62%)

Bajaj Finserv

1957.00

(0.24%)

Bharti Airtel

1852.00

(-0.63%)

Eternal Ltd

234.25

(0.75%)

HCL Technologi..

1575.90

(0.76%)

HDFC Bank

1924.55

(0.04%)

Hind. Unilever

2323.15

(-0.77%)

ICICI Bank

1431.75

(0.65%)

IndusInd Bank

852.25

(1.65%)

Infosys

1506.45

(0.50%)

ITC

430.15

(1.14%)

Kotak Mah. Ban..

2185.00

(-0.94%)

Larsen & Toubr..

3329.35

(-0.34%)

M & M

2930.35

(0.18%)

Maruti Suzuki

12409.20

(1.21%)

Nestle India

2336.80

(-2.04%)

NTPC

348.80

(-1.61%)

Power Grid Cor..

304.05

(-0.85%)

Reliance Indus..

1421.95

(0.97%)

St Bk of India

800.05

(1.51%)

Sun Pharma.Ind..

1828.75

(-0.08%)

Tata Motors

651.85

(1.20%)

Tata Steel

141.30

(1.11%)

TCS

3443.80

(0.41%)

Tech Mahindra

1495.50

(-0.47%)

Titan Company

3339.35

(-1.09%)

UltraTech Cem.

11643.15

(0.03%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Shilpa Medicare receives USFDA approval for Varenicline tablets	Share Back
(09 Apr 2025)
Varenicline helps people quit smoking by blocking the effect of nicotine on the brain. Nicotine is a substance found in cigarettes and other tobacco products that makes smoking feel good. Varenicline blocks this good feeling and can help prevent cravings to smoke cigarettes. The total US market for varenicline products is around $203 million. Shilpa’s product has been approved as a generic version of the innovator, Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year. Shares of Shilpa Medicare tumbled 3.64% to Rs 620.10 on the BSE.
Top